Across TCGA pan-cancer cohorts, OVCA2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated OVCA2 data layer compared with 1 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher OVCA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OVCA2 expression acts as an unfavorable survival marker.
LGG and UCEC are the cancer types where OVCA2 Mutation most reproducibly stratifies survival.